Prestige Biologics Co Ltd
334970
Company Profile
Business description
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).
Contact
197, Osongsaengmyeong 1-ro
Osong-eup, Heungdeok-gu
Chungcheongbuk-do
Cheongju-si28161
KORT: +82 432321552
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
279
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.10 | 5.40 | -0.06% |
| CAC 40 | 8,233.92 | 3.51 | -0.04% |
| DAX 40 | 25,122.26 | 230.06 | 0.92% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,048.21 | 74.52 | -0.74% |
| HKSE | 26,458.95 | 251.50 | -0.94% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,593.90 | 924.18 | -1.76% |
| NZX 50 Index | 13,688.26 | 26.76 | -0.20% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,707.50 | 16.00 | -0.18% |
| SSE Composite Index | 4,085.77 | 2.10 | 0.05% |